AURORA CANNABIS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ACB in the last 30 days.
See all $ACB insider activity →Curaleaf challenged Aurora's rejection of its $5-per-share takeover bid, accusing Aurora of obstructing the process. Decibel Cannabis clarified terms of a $5M share purchase offer from Ewing Morris. Optimi Health completed MDMA production for PTSD trials and commercial supply. Helus Pharma and Filament Health also reported advancements in psychedelic research.
Aurora Cannabis (ACB) rejected a revised $5 per share takeover offer from Curaleaf (CURA), calling it undervalued. Curaleaf, the largest U.S. cannabis producer, launched a hostile bid after Aurora's board urged shareholders to reject the offer. ACB stock has fallen significantly since 2018, and the offer represents a 28% premium to its current price. Shareholders have until Dec. 4, 2026, to tender their shares.
Aurora Cannabis rejected Curaleaf's $5 per share takeover bid, exploring alternatives. Cronos Group acquired Dutch cannabis producer CanAdelaar for €57.5M. Tilray Medical gained Portuguese approval for in-house cannabis quality testing.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning ACB (AURORA CANNABIS INC). Coverage has skewed bullish: 4 bullish, 3 neutral, and 3 bearish.
Recent ACB coverage spans financial news and mergers & acquisitions.
Aurora could experience share price volatility as investors weigh the hostile bid against alternative options.
Share price likely pressured lower as the hostile bid is rejected.
Potential pressure as shareholders consider other offers; no immediate action recommended.
Aurora's rejection may keep its share price depressed amid ongoing takeover speculation.
Shares may face pressure as the market prices in the continued undervaluation and the bid's rejection.
AlphAI scores every news story that mentions ACB with an AI model for sentiment and relevance, and aggregates insider trades from AURORA CANNABIS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Curaleaf challenged Aurora's rejection of its $5-per-share takeover bid, accusing Aurora of obstructing the process. Decibel Cannabis clarified terms of a $5M share purchase offer from Ewing Morris. Optimi Health completed MDMA production for PTSD trials and commercial supply. Helus Pharma and Filament Health also reported advancements in psychedelic research.
3 min readAurora Cannabis (ACB) rejected a revised $5 per share takeover offer from Curaleaf (CURA), calling it undervalued. Curaleaf, the largest U.S. cannabis producer, launched a hostile bid after Aurora's board urged shareholders to reject the offer. ACB stock has fallen significantly since 2018, and the offer represents a 28% premium to its current price. Shareholders have until Dec. 4, 2026, to tender their shares.
2 min readAurora Cannabis rejected Curaleaf's $5 per share takeover bid, exploring alternatives. Cronos Group acquired Dutch cannabis producer CanAdelaar for €57.5M. Tilray Medical gained Portuguese approval for in-house cannabis quality testing.
3 min readCuraleaf (CURA) claims Aurora rejected its enhanced hostile bid, citing an 86% premium to Aurora’s 30-day VWAP. Curaleaf states its bid uses standard conditions and remains ready to engage. Aurora has not granted diligence.
2 min readAurora Cannabis (ACB) advises shareholders to reject Curaleaf's (CURA) revised hostile bid, deeming it undervalued. The board and special committee are exploring strategic alternatives to maximize shareholder value. Aurora's CEO highlights the company's debt-free status and strong cash position. The bid remains open until December 4, 2026.
2 min readAurora Cannabis (ACB) stock rose 25% after Curaleaf (CURLF) raised its takeover offer to $5, a mix of cash and stock. Aurora's board is reviewing the offer, which expires Dec. 4. Aurora is unprofitable but has international expansion plans. Curaleaf's interest may drive further bids, but rejection could cause the stock to fall.
2 min readCuraleaf criticized Aurora Cannabis for considering a merger with Organigram while rejecting its own offer. Curaleaf's revised bid values Aurora at $5.00 per share, including a 25% increase. Aurora's CEO urged shareholders to await a Special Committee's review. Aurora's expansion in Germany is unrelated to the bid, according to the company.
5 min readManitoba proposed cannabis retail safety changes. Trulieve repaid $65M debt, reducing its total to $225M. Aurora reviews Curaleaf's revised $5/share takeover bid. Cannara expanded a supply deal with Curaleaf, potentially worth C$34M. Massachusetts extended a cultivator-license pause until 2027.
7 min readAurora Cannabis (ACB) completed a major expansion of its EU-GMP facility in Germany, doubling annual flower output. The facility, renamed Aurora Horizon, adopts Aurora's cultivation practices and genetics, enhancing production capacity and quality. This expansion supports growing demand in Europe and strengthens Aurora's market position.
1 min readCuraleaf Holdings (TSX:CURA) raised its hostile bid for Aurora Cannabis to US$5 per share, aiming to expand in Canada. CURA's stock is up 30.91% year-to-date but down 65.64% over 5 years. Analysts estimate fair value at CA$18.54, 24% above its current price of CA$14.06, citing growth in international markets and revenue forecasts of US$1.7b.
2 min read
